January 7, 2022

En 2022, Hisense prévoit de commercialiser davantage de produits d’affichage performants et de haute qualité sur le marché africain

JOHANNESBURG, Afrique du Sud, 7 janvier 2022 /PRNewswire/ — Hisense, fournisseur de téléviseurs et d’appareils électroménagers haute performance, a présenté sa solution de technologie d’affichage laser à résolution 8K et la série ULED 8K Mini-LED lors du récent Consumer Electronics Show 2022 (« CES 2022 »), qui s’est tenue à Las Vegas. Suite à la présentation du premier écran laser 8K domestique au monde lors de l’événement technologique le plus influent sur la planète, Hisense présentera en janvier deux autres produits haut de gamme sur le marché africain, ainsi que d’autres produits plus performants plus tard en 2022.

Hisense Plans to Bring More High Performing and High-quality Display Products to African Market in 2022

« Grâce à l’innovation technologique continue, Hisense surmonte les obstacles techniques, faisant passer les téléviseurs laser de 1080P à 2K, puis à 4K et désormais à 8K et propulsant l’industrie mondiale de la télévision laser dans l’ère du TriChroma. Nous nous engageons à apporter des produits dignes de confiance à des millions de nos utilisateurs en Afrique grâce à un design exceptionnel, une technologie de pointe et un excellent service », a déclaré Patrick Hu, directeur marketing d’Hisense South Africa.

Doté du moteur laser TriChroma de Hisense, qui atteint une luminosité maximale de 3 000 lumens, le téléviseur TriChroma L9G sera disponible en Afrique en janvier. Il s’agit d’un téléviseur de projection 4K ultra court avec un triple laser, utilisant des lasers rouges, verts et bleus purs pour atteindre de nouveaux niveaux de performance de couleur. Il a remporté le « King of Ultra Short Throw Projectors », a été nommé « Best in Class » par Projector Reviews et a été désigné comme étant le choix de la rédaction par Projector Central en 2021.

En plus du L9G, Hisense lancera également le téléviseur 4K Mini LED U9G sur le marché africain ce mois-ci. En juin 2022, le nouveau téléviseur 4K Mini LED U8H fera bénéficier les consommateurs de la région d’un plus grand nombre de mises à niveau haut de gamme et de performances de qualité. Avec des tailles d’écran allant de 55 à 75 pouces, le taux de rafraîchissement natif de 120 Hz de l’U8H permet de traiter en douceur mouvements et luminosité, magnifiant à l’écran les films d’action et les sports.

En 2022, Hisense implémente pour la première fois sa technologie Mini LED dans son nouveau téléviseur premium 8K Mini LED, offrant une performance HDR époustouflante avec un meilleur contraste, des images plus lumineuses et des couleurs plus impressionnantes que jamais. Le téléviseur Hisense 8K Mini LED a remporté le prix de l’innovation CES® 2022. Cette technologie de pointe sera également commercialisée sur le marché africain. Le téléviseur phare U80H 8K Mini LED devrait être lancé sur le marché africain en juillet 2022.

Photo – https://mma.prnewswire.com/media/1721327/Hisense.jpg

January 7, 2022

Zenas BioPharma nomme le Dr John Orloff au Conseil d’administration

BOSTON et SHANGHAI, Chine, 06 janv. 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, une société biopharmaceutique mondiale déterminée à devenir un leader dans le développement et la fourniture de traitements immunitaires, a annoncé aujourd’hui la nomination de John Orloff, MD, à son Conseil d’administration. Le Dr Orloff rejoint le Conseil d’administration de Zenas avec plus de 25 ans d’expérience à la tête d’organisations mondiales de recherche et de développement dans plusieurs domaines thérapeutiques, y compris les maladies auto-immunes.

« Nous sommes extrêmement heureux d’accueillir le Dr Orloff au sein du Conseil d’administration de Zenas », a déclaré Lonnie Moulder, fondateur et président exécutif de Zenas. « Le leadership de John et sa vaste expertise dans la recherche, le développement et les affaires médicales et réglementaires seront inestimables alors que nous faisons progresser notre portefeuille de traitements immunitaires innovants et continuons d’étendre notre pipeline via le développement commercial. »

« Je suis ravi de travailler avec l’équipe de direction de Zenas et ses autres directeurs alors que la société progresse rapidement dans un pipeline passionnant de traitements immunitaires », a commenté le Dr Orloff. « Je suis impatient de contribuer au développement continu de la société alors qu’elle s’efforce de remplir sa mission visant à apporter des médicaments innovants aux patients dans le besoin. »

Le Dr Orloff est actuellement partenaire d’investissement chez Agent Capital. À son poste de direction le plus récent, il était vice-président exécutif et responsable de la recherche et du développement chez Alexion où son leadership dans l’expansion du pipeline de développement à 30 programmes a soutenu la récente acquisition d’Alexion par AstraZeneca pour un montant de 39 milliards de dollars.

Avant Alexion, le Dr Orloff a occupé les postes de directeur mondial de la R&D et de directeur scientifique chez Baxalta, ainsi que des postes de direction chez Novelion, Baxter International, Merck Serono, Novartis et Merck Research Laboratories. Avant d’entrer dans l’industrie biopharmaceutique, il était membre du corps professoral de la Yale University School of Medicine. Le Dr Orloff est titulaire d’un diplôme de premier cycle en chimie du Dartmouth College, d’un diplôme de médecine de l’université de Vermont, College of Medicine, et d’une bourse d’études en endocrinologie et métabolisme à la Yale University School of Medicine.

À propos de Zenas BioPharma

Zenas BioPharma est une société biopharmaceutique mondiale basée en Chine et aux États-Unis déterminée à devenir un leader dans le développement et la fourniture de traitements immunitaires pour les patients aux États-Unis, en Chine et dans le monde entier. Zenas fait rapidement progresser un vaste pipeline de traitements innovants qui continue de s’accroître grâce à notre stratégie de développement commercial fructueuse. Notre équipe de direction expérimentée et notre réseau de partenaires commerciaux stimulent l’excellence opérationnelle pour apporter des thérapies potentiellement transformatrices afin d’améliorer la vie des personnes confrontées à des maladies rares et auto-immunes. Pour tout complément d’information sur Zenas BioPharma, veuillez consulter le site www.zenasbio.com et nous suivre sur Twitter à l’adresse @ZenasBioPharma et LinkedIn.

Contact auprès des investisseurs et des médias :
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

January 7, 2022

Zenas BioPharma Nomeia Dr. John Orloff para o Conselho Diretor

BOSTON e XANGAI, China, Jan. 06, 2022 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e entrega de terapias imunológicas, anunciou hoje a nomeação de John Orloff, MD para seu Conselho Diretor. O Dr. Orloff traz para o Conselho da Zenas seus mais de 25 anos de experiência liderando com sucesso organizações globais de pesquisa e desenvolvimento em várias áreas terapêuticas, incluindo doenças autoimunes.

“É com muito prazer que damos as boas-vindas ao Dr. Orloff ao Conselho Diretor da Zenas”, disse Lonnie Moulder, Fundador e Presidente Executivo da Zenas. “A liderança e a ampla experiência em pesquisa, desenvolvimento e assuntos médicos e regulatórios de John serão inestimáveis para o avanço do nosso portfólio de terapêuticas inovadoras com base em imunologia e para a contínua expansão do nosso pipeline por meio do desenvolvimento de negócios.”

“Será um grande prazer trabalhar com a equipe de liderança da Zenas e meus colegas diretores para o avanço rápido da empresa com um emocionante pipeline imunológico”, disse o Dr. Orloff. “Estou pronto para contribuir para o desenvolvimento contínuo da Empresa, no seu esforço em cumprir sua missão de levar medicamentos inovadores para os pacientes que precisam.”

O Dr. Orloff atualmente é sócio de empreendimento da Agent Capital. Na sua função executiva mais recente, ele foi Vice-Presidente Executivo e Chefe de Pesquisa e Desenvolvimento da Alexion, onde sua liderança na expansão do pipeline de desenvolvimento de 30 programas deu suporte à recente aquisição da Alexion pela AstraZeneca, no valor de US$ 39 bilhões.

Antes da Alexion, o Dr. Orloff foi Dirigente Global de P&D e Diretor Científico da Baxalta, e também ocupou cargos de liderança executiva na Novelion, Baxter International, Merck Serono, Novartis e Merck Research Laboratories. Antes de ingressar na indústria biofarmacêutica, ele foi membro do corpo docente da Yale University School of Medicine. O Dr. Orloff é formado em química pelo Dartmouth College, em medicina pelo College of Medicine da University of Vermont, e completou um fellowship em endocrinologia e metabolismo na Yale University School of Medicine.

Sobre a Zenas BioPharma

A Zenas BioPharma é uma empresa biofarmacêutica mundial com sedes nos EUA e na China, comprometida em se tornar líder global no desenvolvimento e oferta de terapias imunológicas para pacientes nos EUA, China e em todo o mundo. A Zenas está avançando rapidamente um vasto pipeline de terapêuticas inovadoras que continua a crescer por meio da nossa estratégia de desenvolvimento de negócios de sucesso. Nossa experiente equipe de liderança e rede de parceiros de negócios impulsionam a excelência operacional para oferecer terapias potencialmente transformadoras para melhorar a vida das pessoas que enfrentam doenças autoimunes e raras. Para mais informação sobre a Zenas BioPharma, visite www.zenasbio.com e siga-nos no Twitter em @ZenasBioPharma e LinkedIn.

Contato com Investidores e com a Mídia:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

January 7, 2022

Djokovic Spends Holiday in Detention, Sends Thanks to Supporters

The top men’s tennis player in the world, Novak Djokovic, spent Orthodox Christmas in an immigration detention hotel in Australia on Friday as he sought to fend off deportation over the country’s COVID-19 rules and compete in the Australian Open.

Djokovic received calls from his native Serbia, including from his parents and the president, who hoped to boost his spirits on the holiday.

On Instagram, he posted: “Thank you to the people around the world for your continuous support. I can feel it and it is greatly appreciated.”

The 34-year-old athlete and vaccine skeptic was barred from entering the country late Wednesday when federal border authorities at the Melbourne airport rejected his medical exemption to Australia’s strict COVID-19 vaccination requirements.

He has been confined to the detention hotel in Melbourne pending a court hearing on Monday, a week before the start of the tournament, where he is seeking to win his record-breaking 21st Grand Slam singles title.

During the day, Djokovic’s supporters, waving banners, gathered outside the Park Hotel, used to house refugees and asylum-seekers.

A priest from the Holy Trinity Serbian Orthodox Church in Melbourne asked to visit the nine-time Australian Open champion to celebrate Orthodox Christmas but was turned down by immigration officials because the hotel is under lockdown.

“Our Christmas is rich in many customs, and it is so important that a priest visits him,” the church’s dean, Milorad Locard, told the Australian Broadcasting Corp. “The whole thing around this event is appalling. That he has to spend Christmas in detention … it is unthinkable.”

The Australian Border Force said Friday that after further investigations into two other people connected to the Australian Open, one voluntarily left the country, and another was taken into detention pending deportation.

The Czech Embassy identified one of them as 38-year-old doubles player Renata Vorácová and said she won’t play in the tournament.

Australia’s COVID-19 rules say incoming travelers must have had two shots of an approved vaccine or must have an exemption with a genuine medical reason, such as an acute condition, to avoid quarantine. All players, staff, officials and fans need to be fully vaccinated against COVID-19 to enter the tournament venue.

Djokovic flew to Australia after obtaining a medical exemption backed by the country’s tennis federation and approved by the Victoria state government. The grounds for the exemption have not been disclosed. But the Australian government pronounced it invalid when he arrived.

The dispute has become a touchy topic in a city where residents spent 256 days in 2020-21 under severe restrictions on their movement. Djokovic’s exemption stirred allegations that the star athlete got special treatment.

While some players have sympathized with his situation, others have said getting vaccinated would have prevented any drama.

But amid the latest turn in the dispute, even some who have been critical of Djokovic in the past are now seemingly in his corner.

“Look, I definitely believe in taking action, I got vaccinated because of others and for my mum’s health, but how we are handling Novak’s situation is bad, really bad,” Nick Kyrgios, an Australian player and outspoken critic of some of Djokovic’s opinions on vaccinations, posted on Twitter. “This is one of our great champions but at the end of the day, he is human. Do better.”

Australian Open tournament director Craig Tiley said earlier this week that 26 people connected with the tournament applied for medical exemptions and only a “handful” were granted. Three of those have since been challenged.

Source: Voice of America

January 7, 2022

US Hiring Slows in December

U.S. employers added 199,000 new jobs in December, 50,000 fewer than November, the Labor Department reported Friday, as business continue to struggle to fill vacancies due to American workers’ reluctance to return to the workforce during the ongoing coronavirus pandemic.

Despite the hiring slowdown, December’s jobless rate fell to a healthy 3.9% — a 22-month low — from November’s 4.2%.

December’s modest jobs gains belie the fact that 2021 was one of the best years for U.S. workers in decades, even though the pandemic caused the previous year to be one of the job market’s worst since the government began tracking hiring in 1939.

A monthly average of 537,000 jobs were added to the economy in 2021, the Labor Department said Friday, and a record 6.4 million jobs were created”America is back to work,” President Biden declared Friday before reporters at the White House. “The increase in Americans joining the labor force was the fastest this year of any year since 1996.”

Companies posted a record high number of job vacancies in 2021 and offered sharply higher pay to try to attract and retain employees, a record number of whom quit their jobs in search of higher-quality positions.

Biden said U.S. workers saw their wages increase last year by nearly 16%, “the highest in history.”

“Wage gains for all workers who are not supervisors went up more in 2021 than any year in four decades. There’s been a lot of press coverage of people quitting their jobs,” Biden said. “Well, today’s report tells you why: Americans are moving up to better jobs with better pay, with better benefits. That’s why they’re quitting their jobs.”

December’s report reflects the state of the economy early in the month, before the highly contagious omicron variant sickened millions of people in the U.S., forcing the cancellation of thousands of commercial flights and leading to reduced traffic at bars and restaurants and some school closures.

Many economists believe job growth may slow in January and possibly in February because of the omicron outbreak, which has forced millions of sick workers to quarantine at home, potentially disrupting employers, including hospitals, airlines and ski resorts.

Source: Voice of America

January 7, 2022

T?KA Supports Lesotho’s Fight against COVID-19

Turkish Cooperation and Coordination Agency (TIKA) provided protective equipment and hygiene products to the Ministry of Foreign Affairs and International Relations of the Kingdom of Lesotho in order to fight against COVID-19.

As part of the project, personal hygiene products such as masks, gloves, and disinfectants; fumigation machines and solution used to clean buildings; and the necessary protective clothing, which were believed to contribute greatly to the fight against COVID-19 as the Omicron variant spreads rapidly in South Africa, were delivered with a ceremony attended by Ms. Mat?epo Ramakoae, Minister of Foreign Affairs and International Relations of Lesotho; Ms. Aysegül Kandas, the Republic of Turkey’s Ambassador to Pretoria; and Abdulkadir Abukan, TIKA’s Coordinator in Pretoria.

In her speech at the ceremony, Ms. Aysegül Kandas, the Republic of Turkey’s Ambassador to Pretoria, underlined that TIKA implemented projects in the fields of agriculture, education, women’s empowerment, and infrastructure, as well as the fight against the pandemic, in Lesotho.

Ms. Mat?epo Ramakoae, Minister of Foreign Affairs and International Relations of Lesotho, also delivered a speech and said that this support was an indication of the ongoing good relations between the people of Turkey and Lesotho, just as other TIKA projects and Türkiye Scholarships.

Source: Government of Turkey